LECT2 and neoplasm: Quantification analysis of US-measured hepatoma diameters showed that Ad-LECT2 therapy significantly relieved the tumor burden of HCC (from 9.01 ± 2.25 mm on day 10–4.72 ± 3.15 mm on day 24; n = 7) in rats compared with control (from 12.96 ± 1.94 mm on day 10–16.86 ± 5.17 mm on day 24; n = 7) or Ad-null (from 11.29 ± 1.96 mm on day 10–15.46 ± 4.20 mm on day 24; n = 7) (Fig. 3F).